Compounds > (4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride
Page last updated: 2024-11-08

(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride and Colitis

(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride has been researched along with Colitis in 1 studies

(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride: A drug that selectively activates certain subclasses of muscarinic receptors and also activates postganglionic nicotinic receptors. It is commonly used experimentally to distinguish muscarinic receptor subtypes.

Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Munyaka, P1
Rabbi, MF1
Pavlov, VA1
Tracey, KJ1
Khafipour, E1
Ghia, JE1

Other Studies

1 other study available for (4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride and Colitis

ArticleYear
Central muscarinic cholinergic activation alters interaction between splenic dendritic cell and CD4+CD25- T cells in experimental colitis.
    PloS one, 2014, Volume: 9, Issue:10

    Topics: (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride; Animals; CD11c Antigen; CD4-Po

2014